# FMT+ QL1706+Bevacizumab+ XELOX as First-line Treatment for Advanced MSS-type Colon Cancer With Liver Metastasis

> **NCT06801665** · PHASE2 · RECRUITING · sponsor: **Hua Jiang** · enrollment: 30 (estimated)

## Conditions studied

- Colon Cancer Liver Metastases

## Interventions

- **COMBINATION_PRODUCT:** FMT+QL1706+Bevacizumab+XELOX

## Key facts

- **NCT ID:** NCT06801665
- **Lead sponsor:** Hua Jiang
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-17
- **Primary completion:** 2027-02-01
- **Final completion:** 2027-02-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06801665

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06801665, "FMT+ QL1706+Bevacizumab+ XELOX as First-line Treatment for Advanced MSS-type Colon Cancer With Liver Metastasis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06801665. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*